Biosimulation startup Entelos just got another patent for its virtual patient software. From the press release:
The software based on this method allows Entelos scientists to rapidly create new virtual patients and effectively use them to validate drug targets, identify biomarkers, translate preclinical data to human outcome, and optimize clinical trial designs.
“By developing this methodology, Entelos can effectively represent patient variability in a computer on both the individual and population scale,” stated James Karis, President and CEO of Entelos. “This ability allows us to address this critical drug development challenge, which is also a key hurdle in fulfilling the promise of personalized medicine. This patent further strengthens our leadership position in biosimulation and lays the framework for Entelos to develop the first-ever virtual human.”
Now there's a twist on intelligent design for you.
(Image via NYU Research).